FORT LAUDERDALE, Fla. — Home OCT offers personalized insights on treatment response for wet age-related macular degeneration that may help reduce treatment burden, according to a speaker.

Vakharia insights from the ARCHER trial on geographic atrophy treatment for dry AMD, highlighting promising results and ...

Candida endophthalmitis is a growing cause of vision loss in candidemia patients. Timely diagnosis, antifungal therapy, and ...

The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.The approval was supported by positive 1-year data from the phase 3 Pavilion study in ...

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...

Susvimo is also approved to treat diabetic macular edema and age-related macular degeneration, and the medication, ...

An oral investigational agent, gildeuretinol (ALK-001), demonstrated a significant reduction in geographic atrophy (GA) lesion growth and improvements in low luminance visual function in the phase II ...

Dr Michael Ekuoba Gyasi, Executive Director of St. Thomas Eye Hospital, was honored as CEO of the Year in Health Care – Eye ...

In a moment that drew applause and admiration from Ghana’s top business and political leaders, Dr. Michael Ekuoba Gyasi, ...

Innovative delivery techniques, including high-tech nanoparticles and electroporationdevices, may convey more gene therapies into the clinic.

Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blin ...

meduniwien.ac.at Aims To investigate the impact of posterior vitreous detachment (PVD) on the efficacy of treat-and-extend (T&E) ranibizumab in neovascular age-related macular degeneration. Methods In ...